RE-BVS – Piemonte Repository

Sfoglia per AUTORE
ARTIOLI G
Collezione AO Ordine Mauriziano

Items : 12

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 May 1;42(13):1488-1498. doi: 10.1200/JCO.23.01225. Epub 2024 Feb 5.

2024
AO Ordine Mauriziano

Lorusso D; Raspagliesi F; Ronzulli D; Valabrega G; Colombo N; Pisano C; Cassani C; Tognon G; Tamberi S; Mangili G; Mammoliti S; De Giorgi U; Greco F; Mosconi AM; Breda E; Artioli G; Andreetta C; Casanova C; Ceccherini R; Frassoldati A; Salutari V; Giolitto S; Scambia G;

Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2024 May;203:114039. doi: 10.1016/j.ejca.2024.114039. Epub 2024 Mar 30.

2024
AO Ordine Mauriziano

Tuninetti V; Virano E; Salutari V; Ricotti A; Pisano C; Ducceschi M; Turitto G; Scandurra G; Petrella MC; Forestieri V; Rizzetto M; Mammoliti S; Artioli G; Cioffi R; Borsotti L; Bellero M; Rognone C; Carbone V; Ferrandina G; Mantiero M; Azzolina C; Geninatti E; Pignata S; Valabrega G;

PARP Inhibitors in Brain Metastases from Epithelial Ovarian Cancer through a Multimodal Patient Journey: Case Reports and Literature Review. in International journal of molecular sciences / Int J Mol Sci. 2024 Jul 18;25(14):7887. doi: 10.3390/ijms25147887.

2024
AO Ordine Mauriziano

Frezzini S; Tasca G; Borgato L; Sartor L; Ferrero A; Artioli G; Modena A; Baldoni A;

Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial. in The International journal of biological markers / Int J Biol Markers. 2024 Dec;39(4):328-337. doi: 10.1177/03936155241296164. Epub 2024 Nov 8.

2024
AO Ordine Mauriziano

Indraccolo S; Signoriello S; Piga I; Esposito G; Ferrarini F; Boscolo Bragadin A; Salutari V; Pisano C; Califano D; Bignotti E; Tognon G; Simeon V; Artioli G; Ferrero A; Cinieri S; Bologna A; Chiodini P; Scognamiglio G; Bottoni C; Spina A; Russo D; Arenare L; Perrone F; Pignata S;

Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society. in Tumori / Tumori. 2023 Oct;109(5):490-495. doi: 10.1177/03008916221146820. Epub 2023 Jan 6.

2023
ASL Torino 5
AO Ordine Mauriziano

Artioli G; Valabrega G; Purro A; Mammoliti S; Testa S; Scotto G; Turinetto M; Bellero M; Milani A; Tuninetti V; Pignata S; Biglia N; Scandurra G; Mangili G; Di Maio M; De Giorgi U; Savarese A; Castaldo D; Lorusso D;

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study. in Cancers / Cancers (Basel). 2023 Feb 6;15(4):1032. doi: 10.3390/cancers15041032.

2023
AO Ordine Mauriziano
AOU Città della Salute di Torino

Borsotti L; Paolini B; Puppo A; Marinaccio M; Cormio G; Carella C; Mandato VD; Parisi A; Sikokis A; Biglia N; Mammoliti S; Zanchi L; Artioli G; Maldi E; Andreetta C; Raspagliesi F; Picardo E; Pignata S; Ghisoni E; Tuninetti V; Scotto G; Turinetto M; Sangiolo D; Di Maio M; Valabrega G;

MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study. in Cancers / Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041.

2023
AO Ordine Mauriziano
AOU Città della Salute di Torino

Tuninetti V; Picardo E; Vertechy L; Bergamini A; Palaia I; Artioli G; Parisi A; Scandurra G; Scollo P; Baldoni A; Malaguti P; Cassani C; Zamagni C; Pisano C; Ricotti A; Marchetti C; Turinetto M; Scotto G; Scambia G; Pignata S; Valabrega G;

Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study. in Gynecologic oncology / Gynecol Oncol. 2023 Aug;175:182-189. doi: 10.1016/j.ygyno.2023.05.065. Epub 2023 Jun 22.

2023
AO Ordine Mauriziano

Colombo N; Gadducci A; Landoni F; Lorusso D; Sabbatini R; Artioli G; Berardi R; Ceccherini R; Cecere SC; Cormio G; De Angelis C; Legge F; Lissoni A; Mammoliti S; Mangili G; Naglieri E; Petrella MC; Ricciardi GRR; Ronzino G; Salutari V; Sambataro D; Savarese A; Scandurra G; Tasca G; Tomao F; Valabrega G; Zavallone L; Pignata S;

Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. in Frontiers in oncology / Front Oncol. 2024 Jan 22;13:1357793. doi: 10.3389/fonc.2023.1357793. eCollection 2023.

2023
AO Ordine Mauriziano

Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Loizzi V; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G; Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; et alii...

Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. in Frontiers in oncology / Front Oncol. 2023 Sep 14;13:1247291. doi: 10.3389/fonc.2023.1247291. eCollection 2023.

2023
AO Ordine Mauriziano

Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey. in Frontiers in oncology / Front Oncol. 2022 May 27;12:880008. doi: 10.3389/fonc.2022.880008. eCollection 2022.

2022
AO Ordine Mauriziano

Giannone G; Castaldo D; Tuninetti V; Scotto G; Turinetto M; Valsecchi AA; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G;

Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society / Int J Gynecol Cancer. 2021 Oct;31(10):1348-1355. doi: 10.1136/ijgc-2021-002786. Epub 2021 Aug 30.

2021
AO Ordine Mauriziano

Gallo C; Schettino C; Gargiulo P; Greggi S; Distefano M; Bogani G; Nardin M; Lapresa M; Cecere SC; Salutari V; Lorusso D; Katsaros D; Lissoni AA; Scollo P; De Giorgi U; Cinieri S; De Censi A; Breda E; Ferrero A; Lauria R; Gadducci A; Tognon G; Artioli G; Frezzini S; Colombo N; Pisano C; Scambia G; Raspagliesi F; Arenare L; et alii...